| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
PRAME (Preferentially expressed antigen in melanoma) is known to be involved in malignancy of various tissues. We performed a gene expression analysis with 100 HCC samples, finding that high PRAME expression in tumor tissue was associated with malignant characteristics such as clinical stage IV, high tumor markar levels, and early recurrence after surgical resection. In non-tumor tissue, PRAME-positive patients showed early recurrence and poor prognosis. Western blot analysis revealed that undifferentiated HCC cells, such as HLE and HLF, showed high level of PRAME expression compared to differentiated HCC cells, PLC/PRF5, HepG2, HuH1, HuH7. Thus, PRAME expression may be a useful marker for a progression and early recurrence of HCC.
We also investigated the molecular mechanism that retinoic acid signaling sensitizes HCC cells to apoptosis induced by sorafenib.
|
